Insider Q&A: Drug Industry Learns to Listen Patients
FDA Approves Immune-Boosting Drug for Advanced Bladder Cancer
U.S. regulators have approved a new drug that harnesses the immune system to treat bladder cancer that has spread after chemotherapy or surgery. The Food and Drug Administration on Monday approved Imfinzi for advanced bladder cancer, along with a companion diagnostic test for identifying which patients are most likely to benefit from it. Imfinzi, also…
New Deals for Drugs: No Heart Attacks or Your Money Back
Pfizer Beats 1Q Profit Forecasts, but Sales Dip Misses Views
Pfizer beat Wall Street expectations for first-quarter profit thanks to reduced spending on operations and legal costs, along with strong sales of key new drugs and longtime blockbuster pain treatment Lyrica. But the top U.S. drugmaker had a disappointing revenue dip of 1 percent as competition hurt overseas sales of the immune disorder drug Enbrel. Sales of Prevnar 13,…
Merck Tops Street 1Q Forecasts on Cost Cuts, New Drug Sales
Strict cost controls, along with surging sales of its two newest medicines and a surprisingly strong performance from its entire vaccine portfolio pushed Merck & Co. beyond most expectations for the first quarter and the company boosted its outlook for the year. The company has begun a new cycle in which sales of its latest drugs grow…
FDA Approves 2nd Near-Copy of Remicade for Immune Disorders
J&J Says Pricing Competition Squeezed 1Q Sales
Johnson & Johnson Says Pricing Competition Squeezed 1Q Sales
Increased pressure to cut medicine prices and an industry-wide slowdown in consumer health product sales is hurting health care giant Johnson & Johnson. Those factors, along with a bigger tax bill than a year ago, trimmed J&J’s first-quarter profit slightly, but it still gave a rosier financial forecast for the year. Revenue was crimped by…
Eli Lilly’s Rheumatoid Arthritis Drug Rejected by Regulators
1st Drug Ok’d For Movement Disorder Caused by Certain Meds
Mallinckrodt to Pay $35M in Deal to End Feds’ Opioid Probe
A top maker of brand-name and generic narcotic painkillers has agreed to pay the U.S. government $35 million to resolve a probe of its distribution of those drugs. Mallinckrodt PLC said Monday it has reached an agreement with the U.S. Drug Enforcement Administration and the U.S. attorneys for the Eastern District of Michigan and Northern…
FDA Approves 1st Drug for Moderate & Severe Eczema Cases
FDA Approves New Drug as Add-On Treatment for Parkinson’s
Activist Investor Ackman’s Hedge Fund Sells Valeant Stake
FDA Oks New Novartis Drug for Type of Advanced Breast Cancer
FDA Approves First Drug to Limit Frequent Waking to Urinate
Insider Q&A: Allergan CEO on Impact of Limiting Price Hikes
Merck Profit Soars on New Drugs, Expects Better 2017
Merck Scores a Hit with Keytruda, Watches Spending in 4Q
Merck & Co.’s new cancer medicine Keytruda, a blockbuster nearly overnight, along with aggressive and ongoing cost cuts, helped to boost fourth-quarter profit by 21 percent. With sales surging for Keytruda and a second newcomer, Zepatier for hepatitis C, the country’s second-biggest drugmaker offset the impact of its latest round of generic competition for longtime…
Pfizer Swings to a 4Q Profit After Rough Year, Hikes 2017 View
J&J to Reveal Average Drug Price Increases
Johnson & Johnson to Reveal Average Drug Price Increases
Johnson & Johnson plans next month to disclose average price increases of its prescription drugs, as the industry tries to calm the storm over soaring prices. The health care giant will divulge its 2016 average increases in list price and net price, or what middlemen such as insurers and distributors pay J&J after discounts and rebates.…
Ex-Valeant, Philidor Execs Arrested for Fraud, Conspiracy
Federal prosecutors have arrested former executives of Valeant Pharmaceuticals and a defunct mail-order pharmacy it helped to establish, charging them with running a high-stakes fraud-and-kickback scheme that bilked the company and its shareholders out of millions of dollars. Thursday’s arrests are part of an ongoing investigation of the scheme, according to Preet Bharara, U.S. Attorney…
